|
π¦
|
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.
13 auth.
A. Roccaro,
A. Sacco,
P. Maiso,
A. Azab,
Y. Tai,
M. Reagan,
F. Azab,
L. Flores,
F. Campigotto,
E. Weller,
...
K. Anderson,
D. Scadden,
I. Ghobrial
|
9 |
2013 |
9
π¦
|
|
π
|
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
24 auth.
A. Azab,
J. Runnels,
C. Pitsillides,
A. Moreau,
F. Azab,
X. Leleu,
X. Jia,
R. Wright,
Beatriz Ospina,
Alicia L. Carlson,
...
C. Alt,
N. Burwick,
A. Roccaro,
H. Ngo,
M. Farag,
Molly R. Melhem,
A. Sacco,
N. Munshi,
T. Hideshima,
B. Rollins,
K. Anderson,
A. Kung,
Charles P. Lin,
I. Ghobrial
|
8 |
2009 |
8
π
|
|
π
|
Targeting the bone marrow microenvironment in multiple myeloma
8 auth.
Y. Kawano,
M. Moschetta,
S. Manier,
S. Glavey,
G. GΓΆrgΓΌn,
A. Roccaro,
...
K. Anderson,
I. Ghobrial
|
8 |
2015 |
8
π
|
|
π¦
|
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.
16 auth.
A. Roccaro,
A. Sacco,
B. Thompson,
X. Leleu,
A. Azab,
F. Azab,
J. Runnels,
X. Jia,
H. Ngo,
Molly R. Melhem,
...
Charles P. Lin,
D. Ribatti,
B. Rollins,
T. Witzig,
K. Anderson,
I. Ghobrial
|
8 |
2009 |
8
π¦
|
|
π
|
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.
18 auth.
A. Azab,
Jinsong Hu,
Phong Quang,
F. Azab,
C. Pitsillides,
R. Awwad,
B. Thompson,
P. Maiso,
Jessica D. Sun,
C. Hart,
...
A. Roccaro,
A. Sacco,
H. Ngo,
Charles P. Lin,
A. Kung,
Ruben D Carrasco,
K. Vanderkerken,
I. Ghobrial
|
8 |
2011 |
8
π
|
|
π¦
|
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
13 auth.
A. Roccaro,
T. Hideshima,
N. Raje,
Shaji K. Kumar,
K. Ishitsuka,
H. Yasui,
N. Shiraishi,
D. Ribatti,
B. Nico,
A. Vacca,
...
F. Dammacco,
P. Richardson,
K. Anderson
|
8 |
2006 |
8
π¦
|
|
π¦
|
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
14 auth.
A. Roccaro,
A. Sacco,
C. JimΓ©nez,
P. Maiso,
M. Moschetta,
Y. Mishima,
Y. Aljawai,
I. Sahin,
M. KuhneΜ,
P. Cardarelli,
...
L. Cohen,
J. S. San Miguel,
R. GarcΓa-Sanz,
I. Ghobrial
|
8 |
2014 |
8
π¦
|
|
π
|
Engineered nanomedicine for myeloma and bone microenvironment targeting
23 auth.
A. Swami,
M. Reagan,
P. Basto,
Y. Mishima,
N. Kamaly,
S. Glavey,
Sufeng Zhang,
M. Moschetta,
Dushanth Seevaratnam,
Yong Zhang,
...
Jinhe Liu,
M. Memarzadeh,
Jun Wu,
S. Manier,
Jinjun Shi,
N. Bertrand,
Z. Lu,
Kenichi Nagano,
R. Baron,
A. Sacco,
A. Roccaro,
O. Farokhzad,
I. Ghobrial
|
8 |
2014 |
8
π
|
|
π
|
Prognostic role of circulating exosomal miRNAs in multiple myeloma.
20 auth.
S. Manier,
Chia-Jen Liu,
H. Avet-Loiseau,
Jihye Park,
Jiantao Shi,
F. Campigotto,
K. Salem,
D. Huynh,
S. Glavey,
Bradley Rivotto,
...
A. Sacco,
A. Roccaro,
Juliette M. Bouyssou,
S. Minvielle,
P. Moreau,
T. Facon,
X. Leleu,
E. Weller,
L. Trippa,
I. Ghobrial
|
7 |
2017 |
7
π
|
|
π¬
|
Regulation of microRNAs in cancer metastasis.
Juliette M. Bouyssou,
S. Manier,
D. Huynh,
S. Issa,
A. Roccaro,
I. Ghobrial
|
7 |
2014 |
7
π¬
|
|
π
|
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
11 auth.
N. Raje,
Shaji K. Kumar,
T. Hideshima,
A. Roccaro,
K. Ishitsuka,
H. Yasui,
...
N. Shiraishi,
D. Chauhan,
N. Munshi,
S. Green,
K. Anderson
|
7 |
2005 |
7
π
|
